乌帕替尼
Tier B — Position earlyUpadacitinib · all drugs expiring in 2033 →
Targets：JAK1
Brand：RINVOQ LQ、Rinvoq Lq、Rinvoq、瑞福
Indications (approved)：斑秃、巨细胞性动脉炎、强直性脊柱炎、椎关节炎、克罗恩病、非放射学性轴性脊柱关节炎、溃疡性结肠炎、银屑病关节炎
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| ABT-494-001 | 1708997-42-5Available | benzyl (3S,4R)-3-ethyl-4-(3-tosyl-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)pyrrolidine-1-carboxylate |
| ABT-494-002 | 1428243-28-0Available | 8-((3R,4S)-4-ethylpyrrolidin-3-yl)-3-tosyl-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazine |
| ABT-494-003 | 753-90-2Available | 2,2,2-trifluoroethan-1-amine |
| ABT-494-004 | - | (3S,4R)-3-ethyl-4-(3-tosyl-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide |
Frequently asked questions
What are the approved indications of Upadacitinib?
Approved indications include: 斑秃, 巨细胞性动脉炎, 强直性脊柱炎, 椎关节炎, 克罗恩病, 非放射学性轴性脊柱关节炎, 溃疡性结肠炎, 银屑病关节炎.
When does the Upadacitinib patent expire?
Based on public sources, the Upadacitinib patent expires in 2033.
How many synthesis routes are recorded for Upadacitinib?
1 synthesis routes are recorded; the shortest is 3 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Upadacitinib intermediates?
3 intermediate CAS of Upadacitinib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Upadacitinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24